Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that several targeted therapies including tyrosine kinase inhibitors (TKIs), such as Bristol-Myers Squibb's Sprycel, Novartis's Gleevec and the anticipated launch of Novartis's Tasigna, will drive robust 12% annual sales growth between 2005 and 2015 in the market to treat acute lymphoblastic leukemia.

The new Pharmacor report entitled Acute Lymphoblastic Leukemia also finds that the diverse disease characteristics of acute lymphoblastic leukemia, including variable age at onset, create significant challenges for drug developers seeking to enter this niche market. The report forecasts that ongoing clinical trials to investigate monoclonal antibodies (MAbs), including Biogen Idec/Genentech/Roche/Zenyaku Kogyo's Rituxan/MabThera and Berlex/Schering AG/Genzyme's Campath, will lead to inclusion of these drugs in first-line chemotherapy regimens by the midpoint of the 2005-2015 study period.

"Clinical data is emerging for second-generation TKIs targeted to the Philadelphia chromosome, an abnormality present in about 30% of adult acute lymphoblastic leukemia patients," said Clair Gricks, Ph.D., analyst Decision Resources. "Although currently available data exists only for the relapse setting of the disease, physicians believe that second generation TKIs have the potential to improve outcomes in the first-line setting. In addition, physicians expect monoclonal antibodies to impact patient outcome to first-line therapy. Enormous unmet need exists to treat acute lymphoblastic leukemia, particularly in the adult patient population where long-term survival is low."

About Acute Lymphoblastic Leukemia

The incidence of acute lymphoblastic leukemia is extremely low, making it a very rare cancer. The duration of first-line therapy is long, up to three years, and physicians report the need for well-tolerated, targeted drugs that can be incorporated into first-line treatment. As a result, significant commercial opportunity exists for well-tolerated, targeted adjunct therapies that are administered chronically.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

While Some Physicians Believe That Inhaled Corticosteroids are Overused for the Treatment of Chronic Obstructive Pulmonary Disease, Majority Say the Drugs Help Treat the Disease

View Now